(Q38908273)

English

The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 September 2017

1 reference

Europe PubMed Central

The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials (English)

1 reference

Europe PubMed Central

7 September 2017

0 references

author name string

Haohai Huang

1

1 reference

Europe PubMed Central

7 September 2017

Guangzhao Chen

2

1 reference

Europe PubMed Central

7 September 2017

Dan Liao

3

1 reference

Europe PubMed Central

7 September 2017

Yongkun Zhu

4

1 reference

Europe PubMed Central

7 September 2017

Rong Pu

5

1 reference

Europe PubMed Central

7 September 2017

Xiaoyan Xue

6

1 reference

Europe PubMed Central

7 September 2017

publication date

26 July 2016

1 reference

Europe PubMed Central

7 September 2017

Obesity Reviews

1 reference

Europe PubMed Central

7 September 2017

17

1 reference

Europe PubMed Central

7 September 2017

12

1 reference

Europe PubMed Central

7 September 2017

1329-1340

1 reference

Europe PubMed Central

7 September 2017

The escalating pandemics of obesity and sedentary lifestyle. A call to action for clinicians

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Assessment of diet quality improves the classification ability of cardiovascular risk score in predicting future events: The 10-year follow-up of the ATTICA study (2002-2012).

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Diet and cardiovascular disease: beyond cholesterol

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Therapeutic potential of resveratrol: the in vivo evidence

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Resveratrol and cardiovascular health

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective.

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men.

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition.

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion.

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults.

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men.

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Blood-pressure reduction and cardiovascular risk in HOPE study

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Effects of intravenous ABT-870 (iron (III)-hydroxide oligosaccharide) on mean arterial pressure and heart rate in the anaesthetized beagle: comparison with other iron-containing haematinic agents

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats.

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Central administration of resveratrol improves diet-induced diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Obesity, inflammation and the immune system

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Inflammation and metabolic dysfunction: links to cardiovascular diseases

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Biomarkers for the prediction of type 2 diabetes and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

One-Year Consumption of a Grape Nutraceutical Containing Resveratrol Improves the Inflammatory and Fibrinolytic Status of Patients in Primary Prevention of Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1111%2FOBR.12458

21 January 2018

Identifiers

10.1111/OBR.12458

1 reference

Europe PubMed Central

7 September 2017

1 reference

Europe PubMed Central

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38908273&oldid=1795798568"